Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

• Status: Not yet recruiting
• Trial end date: 2022-09-19
• Target enrollment: 0
• Participant gender: All

Summary

This study is a phase II, multicenter, randomized, double-blind, placebo-controlled, seamless adaptive design clinical study, aiming to evaluate the safety and effectiveness of three doses of ASC42 matched placebo in subjects with primary biliary cholangitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gannex Pharma Co., Ltd.

Criteria

Inclusion Criteria:

• Age ≥ 18 and ≤75 years old at screening.

• Definite or probable PBC diagnosis, as demonstrated by the presence of ≥ 2 of the following 3 diagnostic factors:

1. Biochemical evidence of cholestasis based on ALP elevation.

2. Presence of AMA, or other PBC-specific autoantibodies, including sp100 or gp210, if AMA is negative.

3. Liver biopsy consistent with PBC.

• Screening ALP ≥ 1.67× ULN

• Taking UDCA for at least 6 months (stable dose for ≥ 3 months) prior to Day 0, or unable to tolerate UDCA (no UDCA for ≥ 3 months) prior to Day 0.

Exclusion Criteria:

• ALT or AST > 5× ULN; ALP >10× ULN

• History or presence of other concomitant liver diseases

• Child-Pugh grade B or C